CA2324060A1 - Methods and compounds for modulating nuclear receptor activity - Google Patents
Methods and compounds for modulating nuclear receptor activity Download PDFInfo
- Publication number
- CA2324060A1 CA2324060A1 CA002324060A CA2324060A CA2324060A1 CA 2324060 A1 CA2324060 A1 CA 2324060A1 CA 002324060 A CA002324060 A CA 002324060A CA 2324060 A CA2324060 A CA 2324060A CA 2324060 A1 CA2324060 A1 CA 2324060A1
- Authority
- CA
- Canada
- Prior art keywords
- atom
- receptors
- leu
- receptor
- nuclear receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7995698P | 1998-03-30 | 1998-03-30 | |
US11314698P | 1998-12-16 | 1998-12-16 | |
US11301498P | 1998-12-16 | 1998-12-16 | |
US60/113,146 | 1998-12-16 | ||
US60/079,956 | 1998-12-16 | ||
US60/113,014 | 1998-12-16 | ||
PCT/US1999/006937 WO1999050658A2 (en) | 1998-03-30 | 1999-03-30 | Methods and compounds for modulating nuclear receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2324060A1 true CA2324060A1 (en) | 1999-10-07 |
Family
ID=27373576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002324060A Abandoned CA2324060A1 (en) | 1998-03-30 | 1999-03-30 | Methods and compounds for modulating nuclear receptor activity |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1144997A3 (de) |
JP (1) | JP2002516983A (de) |
KR (1) | KR20010042373A (de) |
AU (1) | AU3457199A (de) |
CA (1) | CA2324060A1 (de) |
WO (1) | WO1999050658A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6965850B2 (en) * | 1998-03-30 | 2005-11-15 | The Regents Of The University Of California | Methods for modulating nuclear receptor coactivator binding |
AU2818200A (en) * | 1999-03-01 | 2000-09-21 | Karo Bio Ab | Homology models of the glucocorticoid receptor |
JP2003511467A (ja) | 1999-10-14 | 2003-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | アンドロゲンレセプターリガンド結合ドメインの結晶構造 |
FR2801311B1 (fr) | 1999-11-22 | 2005-08-26 | Centre Nat Rech Scient | Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d |
EP1297175A4 (de) * | 2000-06-30 | 2005-02-02 | Univ California | Verfahren und verbindungen zur modulation der bindung von nukleärem rezeptor am koaktivator |
DE10036461A1 (de) * | 2000-07-25 | 2002-02-07 | Bayer Ag | Ligandenbindedomäne des Ultraspiracle (USP)-Proteins |
JP4593754B2 (ja) * | 2000-10-13 | 2010-12-08 | 一般財団法人 化学物質評価研究機構 | 化学物質の50%阻害濃度決定方法 |
JP2002296282A (ja) * | 2001-04-02 | 2002-10-09 | Enbiotec Laboratories:Kk | 外因性内分泌攪乱物質の検出方法 |
WO2003005025A1 (en) * | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
GB0209507D0 (en) * | 2002-04-25 | 2002-06-05 | Karobio Ab | Nuclear receptor structure |
US7302347B2 (en) * | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
JPWO2005022436A1 (ja) * | 2003-08-29 | 2006-10-26 | 独立行政法人産業技術総合研究所 | 蛋白質機能発現機構表示のための蛋白質構造三次元表示システム |
US7264813B2 (en) | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
JP2007535906A (ja) * | 2003-10-24 | 2007-12-13 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 直交遺伝子スイッチ |
CN102905685A (zh) * | 2010-03-31 | 2013-01-30 | 株式会社爱茉莉太平洋 | 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物 |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
US9193714B2 (en) | 2011-12-14 | 2015-11-24 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
CA2118806A1 (en) * | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
DE69434998T2 (de) * | 1993-05-27 | 2008-03-13 | Aventis Pharmaceuticals Inc. | Topologisch getrennte, kodierende Festphasen-Bibliotheken |
IL106106A0 (en) * | 1993-06-22 | 1993-10-20 | Interpharm Lab Ltd | Library of polymeric molecules and its preparation |
WO1997021993A2 (en) * | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
-
1999
- 1999-03-30 KR KR1020007010940A patent/KR20010042373A/ko not_active Application Discontinuation
- 1999-03-30 EP EP99916206A patent/EP1144997A3/de not_active Withdrawn
- 1999-03-30 JP JP2000541516A patent/JP2002516983A/ja not_active Withdrawn
- 1999-03-30 CA CA002324060A patent/CA2324060A1/en not_active Abandoned
- 1999-03-30 AU AU34571/99A patent/AU3457199A/en not_active Abandoned
- 1999-03-30 WO PCT/US1999/006937 patent/WO1999050658A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU3457199A (en) | 1999-10-18 |
WO1999050658A2 (en) | 1999-10-07 |
WO1999050658A3 (en) | 2001-08-16 |
EP1144997A2 (de) | 2001-10-17 |
KR20010042373A (ko) | 2001-05-25 |
EP1144997A3 (de) | 2002-08-28 |
JP2002516983A (ja) | 2002-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2324060A1 (en) | Methods and compounds for modulating nuclear receptor activity | |
AU768513B2 (en) | Methods and compounds for modulating nuclear receptor coactivator binding | |
Wong et al. | Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine | |
Masson et al. | An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery | |
Dauden et al. | Architecture of the yeast Elongator complex | |
Pereira de Jésus‐Tran et al. | Comparison of crystal structures of human androgen receptor ligand‐binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity | |
AU775928B2 (en) | Crystallographic structure of the androgen receptor ligand binding domain | |
Dauter et al. | Practical experience with the use of halides for phasing macromolecular structures: a powerful tool for structural genomics | |
Lu et al. | Conformational landscape of the p28-bound human proteasome regulatory particle | |
Kosteria et al. | The use of proteomics in assisted reproduction | |
EP1034184A2 (de) | Kernrezeptor-liganden und liganden bindende domänen | |
Sun et al. | Research advances in hydrogen–deuterium exchange mass spectrometry for protein epitope mapping | |
AU2014361662A1 (en) | Systems and methods of selecting compounds with reduced risk of cardiotoxicity | |
US20090088554A1 (en) | Hdm2-inhibitor complexes and uses thereof | |
Wang et al. | Pan-cancer analysis of voltage-dependent anion channel (VDAC1) as a cancer therapeutic target or diagnostic biomarker | |
WO2002002488A9 (en) | Methods and compounds for modulating nuclear receptor coactivator binding | |
EP3042205A1 (de) | Verfahren zur verbesserung einer antikörperstabilität | |
Trauger et al. | Investigating viral proteins and intact viruses with mass spectrometry | |
AU2003262215A1 (en) | Methods and compounds for modulating nuclear receptor activity | |
Suchanova et al. | Folding and assembly of large macromolecular complexes monitored by hydrogen-deuterium exchange and mass spectrometry | |
Tessier et al. | Structural and functional validation of a highly specific Smurf2 inhibitor | |
Wiklund | Metabolomics and prostate cancer | |
Nguyen et al. | Genome mining yields new disease-associated ROMK variants with distinct defects | |
CA2564584A1 (en) | Hdm2-inhibitor complexes and uses thereof | |
WO2003095487A2 (en) | Immunogenic cd1 complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |